Table 4.

Indirect thrombin inhibitor trials and outcomes

Trial	Study drug	N	10 endpoints	Outcomes/comments
SYNERGY	Enoxaparin UFH	2,323 2,364	Composite of death and MI @ 30 days	No difference between 2 groups Trend towards ↑ TIMI major bleeding with enoxaparin (P = 0.28) No difference in GUSTO severe bleeding between 2 groups
OASIS-6	Fondaparinux 2.5 mg UFH for 4–48 h	3,788 (total)* 1,890 (Fondaparinux) 1,898 (UFH)	Composite of death or reinfarction	No difference in composite endpoints between 2 groups No difference in bleeding complications Increased catheter thrombosis with fondaparinux (P < 0.001) Of the 21% in the fondaparinux group receiving UFH before 10 PCI, rates of coronary complications, catheter thrombosis, and severe bleeding were similar to control group

^*Notes: Patients with STEMI undergoing primary PCI.

Abbreviation: N, number of patients.